Histone deacetylase inhibitors: An attractive therapeutic strategy against breast cancer

Anticancer Research

Volumn 37, Issue 1, 2017, Pages 35-46

  Damaskos, Christos ^a   Valsami, Serena ^b   Kontos, Michael ^a   Spartalis, Eleftherios ^a   Kalampokas, Theodoros ^b   Kalampokas, Emmanouil ^c   Athanasiou, Antonios ^a   Moris, Demetrios ^d   Daskalopoulou, Afrodite ^a,e   Davakis, Spyridon ^a   Tsourouflis, Gerasimos ^a   Kontzoglou, Konstantinos ^a   Perrea, Despina ^a   Nikiteas, Nikolaos ^a   Dimitroulis, Dimitrios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acetylation; Breast; Cancer; Epigenetics; HDAC; Histone; Inhibitors; Review; Targeted; Therapy

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; BUTYRIC ACID; ENTINOSTAT; FERROCENYL; FINGOLIMOD; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; N (2 HYDROXYPHENYL) 2 PROPYLPENTANAMIDE; OCTANEDIOIC ACID [3 [2 (5 METHOXY 1H INDOL 1 YL)PHENYL] AMIDE N HYDROXYAMIDE; PANOBINOSTAT; SANTACRUZAMATE A; SIRTUIN; SK 7041; SUBEROYLBIS HYDROXAMIC ACID; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG MECHANISM; EPIGENETICS; HISTONE ACETYLATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; BREAST NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHROMATIN ASSEMBLY AND DISASSEMBLY; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 85007574645     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11286     Document Type: Review

References (127)

1. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO and Jemal A: International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 24: 1495-1506, 2015.
2. Nyante SJ, Lee SS, Benefield TS, Hoots TN and Henderson LM: The association between mammographic calcifications and breast cancer prognostic factors in a population-based registry cohort. Cancer 2016. doi: 10.1002/cncr.30281
3. Rexer BN and Arteaga CL: Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 17: 1-16, 2012.
4. Giuliano M, Schifp R, Osborne CK and Trivedi MV: Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast 20(Suppl 3): S42-49, 2011.
5. Tryfonidis K, Zardavas D, Katzenellenbogen BS and Piccart M: Endocrine treatment in breast cancer: Cure, resistance and beyond. Cancer Treat Rev 50: 68-81, 2016.
6. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C and Aparicio S: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352, 2012.
7. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE and Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
8. Cho N: Molecular subtypes and imaging phenotypes of breast cancer. Ultrasonography 35: 281-2888, 2016.
9. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P and Birnbaum D: How basal are triple-negative breast cancers? Int J Cancer 123: 236-240, 2008.
10. Hosford SR and Miller TW: Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med 7: 203-215, 2014.
11. Marks DL, Olson RL and Fernandez-Zapico ME: Epigenetic control of the tumor microenvironment. Epigenomics 2016. doi:10.2217/epi-2016-0110
12. Jones P: The cancer epigenome. Genome 56: 540-541, 2013.
13. Rando OJ and Ahmad K: Rules and regulation in the primary structure of chromatin. Curr Opin Cell Biol 19: 250-256, 2007.
14. Woo YM: Epigenetic Regulation in Cystogenesis. Adv Exp Med Biology 933: 59-68, 2016.
15. Kuo MH and Allis CD: Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20: 615-626, 1998.
16. Inche AG and La Thangue NB: Chromatin control and cancerdrug discovery: realizing the promise. Drug Discov Today 11: 97-109, 2006.
17. Kouzarides T: Chromatin modifications and their function. Cell 128: 693-705, 2007.
18. Haberland M, Montgomery RL and Olson EN: The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42, 2009.
19. Trapp J and Jung M: The role of NAD+ dependent histone deacetylases (sirtuins) in ageing. Curr Drug Targets 7: 1553-1560, 2006.
20. Olzscha H, Sheikh S and La Thangue NB: Deacetylation of chromatin and gene expression regulation: A new target for epigenetic therapy. Crit Rev Oncog 20: 1-17, 2015.
21. Li A, Liu Z, Li M, Zhou S, Xu Y, Xiao Y and Yang W: HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer. Oncotarget 7: 37966-37978, 2016.
22. Krusche CA, Wülfing P, Kersting C, Vloet A, Böcker W, Kiesel L, Beier HM and Alfer J: Histone deacetylase-1 and-3 protein expression in human breast cancer: A tissue microarray analysis. Breast Cancer Res Treat 90: 15-23, 2005.
23. Stojanovic N, Hassan Z, Wirth M, Wenzel P, Beyer M, Schäfer C, Brand P, Kroemer A, Stauber RH, Schmid RM, Arlt A, Sellmer A, Mahboobi S, Rad R, Reichert M, Saur D, Krämer OH and Schneider G: HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Oncogene 2016. doi: 10.1038/onc.2016.344
24. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S and Iwase H: Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat 94: 11-16, 2005.
25. Taunton J, Hassig CA and Schreiber SL: A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272: 408-411, 1996.
26. Ng HH and Bird A: Histone deacetylases: silencers for hire. Trends Biochem Sci 25: 121-126, 2000.
27. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE and Robson CN: Upregulation and nuclear recruitment of HDAC1 in hormone-refractory prostate cancer. Prostate 59: 177-189, 2004.
28. Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH and Kim DY: Down-regulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol 19: 218-224, 2004.
29. Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba H, Kohnoe S, Yonemasu H, Hachitanda Y, Okamura T and Sugimachi K: Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep 10: 333-338, 2003.
30. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH and Davidsen SK: Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310: 529-536, 2003.
31. Kawai H, Li H, Avraham S, Jiang S and Avraham HK: Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 107: 353-358, 2003.
32. Khochbin S, Verdel A, Lemercier C and Seigneurin-Berny D: Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 11: 162-166, 2001.
33. Meehan WJ, Samant RS, Hopper JE, Carrozza MJ, Shevde LA, Workman JL, Eckert KA, Verderame MF and Welch DR: Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the MSIN3 histone deacetylase complex and represses transcription. J Biol Chem 279: 1562-1569, 2004.
34. New M, Olzscha H and La Thangue NB: HDAC inhibitor-based therapies: Can we interpret the code? Mol Oncol 6: 637-656, 2012.
35. Marks PA: The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 19: 1049-1066, 2010.
36. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, Verbois L, Morse DE, Jee JM, Pope S, Harapanhalli RS, Dagher R, Farrell A, Justice R and Pazdur R: Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 13: 2318-2322, 2007.
37. Marks PA: Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356, 2007.
38. Barbarotta L and Hurley K: Romidepsin for the treatment of peripheral T-Cell lymphoma. J Adv Pract Oncol 6: 22-36, 2015.
39. Libby EN, Becker PS, Burwick N, Green DJ, Holmberg L and Bensinger WI: Panobinostat: A review of trial results and future prospects in multiple myeloma. Expert Rev Hematol 8: 9-18, 2015.
40. Damaskos C, Valsami S, Spartalis E, Antoniou EA, Tomos P, Karamaroudis S, Zoumpou T, Pergialiotis V, Stergios K, Michaelides C, Kontzoglou K, Perrea D, Nikiteas N and Dimitroulis D: Histone deacetylase inhibitors: A novel therapeutic weapon against medullary thyroid cancer? Anticancer Res 36: 5019-5024, 2016.
41. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M and Minton SE: A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104: 1828-1835, 2011.
42. Chen S, Ye J, Kijima I and Evans D: The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci USA 107: 11032-11037, 2010.
43. Schech A, Kazi A, Yu S, Shah P and Sabnis G: Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells. Mol Cancer Ther 14: 1848-1857, 2015.
44. Chiu HW, Yeh YL, Wang YC, Huang WJ, Ho SY, Lin P and Wang YJ: Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model. Mol Cancer 15: 46, 2016.
45. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R and Pavletich NP: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193, 1999.
46. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA and Richon VM: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61: 8492-8497, 2001.
47. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V and Bhalla K: Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of HER2. Clin Cancer Res 11: 6382-6389, 2005.
48. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C and Frankel SR: Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26: 81-87, 2008.
49. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR and Somlo G: A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study. Clin Cancer Res 14: 7138-7142, 2008.
50. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P and Kelly WK: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24: 166-173, 2006.
51. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
52. Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR and Munster PN: HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 8: 794-801, 2009.
53. Wu S, Luo Z, Yu PJ, Xie H and He YW: Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial-mesenchymal transition of triple-negative breast cancer cells via HDAC8/FOXA1 signals. Biol Chem 397: 75-83, 2016.
54. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008.
55. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
56. Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY and Koeffler HP: FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer 120: 1013-1022, 2007.
57. Kim YJ, Greer CB, Cecchini KR, Harris LN, Tuck DP and Kim TH: HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade. Oncogene 32: 2828-2835, 2013.
58. Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X and Chen X: Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 32: 599-609, 2013.
59. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE and Tari LW: Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12: 1325-1334, 2004.
60. Hu E, Chen Z, Fredrickson T, Zhu Y, Kirkpatrick R, Zhang GF, Johanson K, Sung CM, Liu R and Winkler J: Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem 275: 15254-15264, 2000.
61. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, Fischer M and Witt O: Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 15: 91-99, 2009.
62. Yoshida M, Horinouchi S and Beppu T: Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17: 423-430, 1995.
63. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I and Coombes RC: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971-976, 2001.
64. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG and Davidson NE: Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60: 6890-6894, 2000.
65. Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC and Vigushin DM: Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 10: 8094-8104, 2004.
66. Ning L, Jaskula-Sztul R, Kunnimalaiyaan M and Chen H: Suberoyl bishydroxamic acid activates NOTCH1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma. Ann Surg Oncol 15: 2600-2605, 2008.
67. You BR and Park WH: Suberoyl bishydroxamic acid inhibits the growth of A549 lung cancer cells via caspase-dependent apoptosis. Mol Cell Biochem 344: 203-210, 2010.
68. Zhuang ZG, Fei F, Chen Y and Jin W: Suberoyl bis-hydroxamic acid induces p53-dependent apoptosis of MCF-7 breast cancer cells. Acta Pharmacol Sin 29: 1459-1466, 2008.
69. Yang X, Zhang N, Shi Z, Yang Z and Hu X: Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells. Mol Med Rep 11: 2908-2912, 2015.
70. Yoon MK, Mitrea DM, Ou L and Kriwacki RW: Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 40: 981-988, 2012.
71. Jiang D, Wang X, Liu X and Li F: Gene delivery of cyclindependent kinase inhibitors p21WAF1 and p27KIP1 suppresses proliferation of MCF-7 breast cancer cells in vitro. Breast Cancer 21: 614-623, 2014.
72. Danial NN: BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clinical Cancer Res 13: 7254-7263, 2007.
73. Cregan SP, MacLaurin JG, Craig CG, Robertson GS, Nicholson DW, Park DS, and Slack RS: BAX-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J Neurosci 19: 7860-7869, 1999.
74. Ganai SA: Panobinostat: The small molecule metalloenzyme inhibitor with marvelous anticancer activity. Curr Top Med Chem 16: 427-434, 2016.
75. Zhou Q, Atadja P and Davidson NE: Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther 6: 64-69, 2007.
76. Kubo M, Kanaya N, Petrossian K, Ye J, Warden C, Liu Z, Nishimura R, Osako T, Okido M, Shimada K, Takahashi M, Chu P, Yuan YC and Chen S: Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Res Treat 137: 93-107, 2013.
77. Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME and Collins-Burow BM: Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res 14: R79, 2012.
78. Tan WW, Allred JB, Moreno-Aspitia A, Northfelt DW, Ingle JN, Goetz MP and Perez EA: Phase I study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients. Clin Breast Cancer 16: 82-86, 2016.
79. Scheel C and Weinberg RA: Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 22: 396-403, 2012.
80. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.
81. Van Horssen R, Hollestelle A, Rens JA, Eggermont AM, Schutte M and Ten Hagen TL: E-Cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells. Breast Cancer Res Treat 136: 365-377, 2012.
82. Shah P, Gau Y and Sabnis G: Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin. Breast Cancer Res Treat 143: 99-111, 2014.
83. Naldini A, Filippi I, Cini E, Rodriquez M, Carraro F and Taddei M: Downregulation of hypoxia-related responses by novel antitumor histone deacetylase inhibitors in MDAMB231 breast cancer cells. Anticancer Agents Med Chem 12: 407-413, 2012.
84. Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, Buchholz TA and Woodward WA: Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling. Stem Cells 30: 2366-2377, 2012.
85. Giudice FS, Pinto DS Jr, Nor JE, Squarize CH and Castilho RM: Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PloS One 8: e58672, 2013.
86. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ and Trepel JB: Randomized phase II, double-blind, placebocontrolled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 31: 2128-2135, 2013.
87. Sami S, Hoti N, Xu HM, Shen Z and Huang X: Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem 144: 357-362, 2008.
88. Kurwale N, Garg K, Arora A, Chandra PS and Tripathi M: Valproic acid as an antiepileptic drug: Is there a clinical relevance for the epilepsy surgeon? Epilepsy Res 127: 191-194, 2016.
89. Peselow ED, Clevenger S and IsHak WW: Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: A naturalistic study. Int Clin Psychopharmacol 31: 218-223, 2016.
90. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG and Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001.
91. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K and Denk H: Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5: 2203-2210, 2006.
92. Fortunati N, Bertino S, Costantino L, Bosco O, Vercellinatto I, Catalano MG and Boccuzzi G: Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett 259: 156-164, 2008.
93. Travaglini L, Vian L, Billi M, Grignani F and Nervi C: Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol 41: 225-234, 2009.
94. Zhang L, Wang G, Wang L, Song C, Leng Y, Wang X and Kang J: VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin. Mol Cell Biochem 361: 39-45, 2012.
95. Mawatari T, Ninomiya I, Inokuchi M, Harada S, Hayashi H, Oyama K, Makino I, Nakagawara H, Miyashita T, Tajima H, Takamura H, Fushida S and Ohta T: Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through HSP70 acetylation. Int J Oncol 47: 2073-2081, 2015.
96. Pratt WB and Toft DO: Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 228: 111-133, 2003.
97. Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, Scogliamiglio G, Russo D, D'Angelo G, Franco R, Budillon A, Di Gennaro E: Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget 7: 7715-7731, 2016.
98. Xiong F, Mou YZ and Xiang XY: Inhibition of mouse B16 melanoma by sodium butyrate correlated to tumor associated macrophages differentiation suppression. Int J Clin Exp Med 8: 4170-4174, 2015.
99. Demary K, Wong L and Spanjaard RA: Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 163: 103-107, 2001.
100. Jazirehi AR: Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anticancer Drugs 21: 805-813, 2010.
101. Li L, Sun Y, Liu J, Wu X, Chen L, Ma L and Wu P: Histone deacetylase inhibitor sodium butyrate suppresses DNA double strand break repair induced by etoposide more effectively in MCF-7 cells than in HEK293 cells. BMC Biochem 16: 2, 2015.
102. Greenberg VL, Williams JM, Boghaert E, Mendenhall M, Ain KB and Zimmer SG: Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells. Thyroid 11: 21-9, 2001.
103. Chopin V, Toillon RA, Jouy N and Le Bourhis X: Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells. Br J Pharmacol 135: 79-86, 2002.
104. Tor YS, Yazan LS, Foo JB, Armania N, Cheah YK, Abdullah R, Imam MU, Ismail N and Ismail M: Induction of apoptosis through oxidative stress-related pathways in MCF-7, human breast cancer cells, by ethyl acetate extract of Dillenia suffruticosa. BMC Complement Altern Med 14: 55, 2014.
105. Wang Y, Hu PC, Ma YB, Fan R, Gao FF, Zhang JW and Wei L: Sodium butyrate-induced apoptosis and ultrastructural changes in MCF-7 breast cancer cells. Ultrastruct Pathol 40: 200-204, 2016.
106. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T and Nakanishi O: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96: 4592-4597, 1999.
107. Lee KW, Kim JH, Park JH, Kim HP, Song SH, Kim SG, Kim TY, Jong HS, Jung KH, Im SA, Kim TY, Kim NK and Bang YJ: Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. Anticancer Res 26: 3429-3438, 2006.
108. Park JH, Jung Y, Kim TY, Kim SG, Jong HS, Lee JW, Kim NK, Kim TY and Bang YJ: Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 2004 10: 5271-5281, 2004.
109. Ryu JK, Lee WJ, Lee KH, Hwang JH, Kim YT, Yoon YB and Kim CY: SK-7041, a new histone deacetylase inhibitor, induces G2-M cell-cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett 237: 143-154, 2006.
110. Hait NC, Avni D, Yamada A, Nagahashi M, Aoyagi T, Aoki H, Dumur CI, Zelenko Z, Gallagher EJ, Leroith D, Milstien S, Takabe K and Spiegel S: The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer. Oncogenesis 4: e156, 2015.
111. Prestegui-Martel B, Bermudez-Lugo JA, Chavez-Blanco A, Duenas-Gonzalez A, Garcia-Sanchez JR, Perez-Gonzalez OA, Padilla-Martínez II, Fragoso-Vázquez MJ, Mendieta-Wejebe JE, Correa-Basurto AM, Méndez-Luna D, Trujillo-Ferrara J and Correa-Basurto J: N-(2-Hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells. J Enzyme Inhib Med Chem 2: 1-10, 2016.
112. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001.
113. Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D and Davidson NE: A novel histone deacetylase inhibitor, Scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER-negative human breast cancer cells in combination with 5-aza-2'-deoxycytidine. Breast Cancer Res Treat 81: 177-186, 2003.
114. Huang WJ, Chen CC, Chao SW, Yu CC, Yang CY, Guh JH, Lin YC, Kuo CI, Yang P and Chang CI: Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors. Eur J Med Chem 46: 4042-4049, 2011.
115. Huang WJ, Tang YA, Chen MY, Wang YJ, Hu FH, Wang TW, Chao SW, Chiu HW, Yeh YL, Chang HY, Juan HF, Lin P and Wang YC: A histone deacetylase inhibitor YCW1 with antitumor and anti-metastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies. Cancer Lett 346: 84-93, 2014.
116. Wang TT and Phang JM: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55: 2487-2489, 1995.
117. Hanna RA, Quinsay MN, Orogo AM, Giang K, Rikka S and Gustafsson AB: Microtubule-associated protein 1 light chain 3 (LC3) interacts with BNIP3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy. J Biol Chem 287: 19094-19104, 2012.
118. Zhang J and Ney PA: Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ 16: 939-946, 2009.
119. Burton TR, Eisenstat DD and Gibson SB: BNIP3 (BCL-2 19 kDa interacting protein) acts as transcriptional repressor of apoptosisinducing factor expression preventing cell death in human malignant gliomas. J Neurosci 29: 4189-4199, 2009.
120. Sowter HM, Ferguson M, Pym C, Watson P, Fox SB, Han C and Harris AL: Expression of the cell death genes BNIP3 and NIX in ductal carcinoma in situ of the breast; correlation of BNIP3 levels with necrosis and grade. J Pathol 201: 573-580, 2003.
121. Gromek SM, deMayo JA, Maxwell AT, West AM, Pavlik CM, Zhao Z, Li J, Wiemer AJ, Zweifach A and Balunas MJ: Synthesis and biological evaluation of santacruzamate A analogues for antiproliferative and immunomodulatory activity. Bioorg Med Chem 24: 5183-5196, 2016.
122. Li C, Tang C, Hu Z, Zhao C, Li C, Zhang S, Dong C, Zhou HB, Huang J: Synthesis and structure-activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy. Bioorg Med Chem 24: 3062-3074, 2016.
123. Rodriguez-Paredes M and Esteller M: Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339, 2011.
124. Slingerland M, Guchelaar HJ and Gelderblom H: Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs 25: 140-149, 2014.
125. Fan J, Yin WJ, Lu JS, Wang L, Wu J, Wu FY, Di GH, Shen ZZ and Shao ZM: ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol 134: 883-890, 2008.
126. Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ and Lee JS: The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23: 1724-1736, 2004.
127. Thomas S, Thurn KT, Bicaku E, Marchion DC and Munster PN: Addition of a histone deacetylase inhibitor redirects tamoxifentreated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat 130: 437-447, 2011.